StocksMedium•9 November 2026•
1 min read
Zealand Pharma Survodutide Meets Primary Endpoints in Phase 3 Obesity Trial
Key Facts
1Zealand Pharma announced that survodutide met its primary endpoints in the Phase 3 SYNCHRONIZE-CVOT trial, demonstrating cardiovascular safety.
Zealand Pharma announced that survodutide met its primary endpoints in the Phase 3 SYNCHRONIZE-CVOT trial, demonstrating cardiovascular safety. GlobeNewswire reported that the drug showed no increased risk of major adverse cardiovascular events compared to a placebo in adults living with obesity or overweight and associated health risks.
Secondary results from the trial, conducted by Zealand Pharma and Boehringer Ingelheim, showed meaningful weight loss of up to 13.7% over 72 weeks alongside improvements in cardiometabolic health biomarkers. ZLDPF closed at $34.6 on November 6, 2026.